Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type

Archives of Dermatology

Volumn 148, Issue 5, 2012, Pages 613-620

  Apisarnthanarax, Narin ^a,d   Wood, Gary S ^a,c,e   Stevens, Seth R ^a,c,f   Carlson, Sean ^a,g   Chan, Derek V ^a,h   Liu, Lili ^a   Szabo, Sarolta K ^a,i   Fu, Pingfu ^b   Gilliam, Anita C ^a,j   Gerson, Stanton L ^a   Remick, Scot C ^a,k   Cooper, Kevin D ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^d Clear Lake Dermatology   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f WOODLAND HILLS MEDICAL CENTER   (United States)

^g AULTMAN HOSPITAL   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ Alta Vista Dermatology   (United States)

^j PALO ALTO MEDICAL FOUNDATION   (United States)

^k WEST VIRGINIA UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O BENZYLGUANINE; CARMUSTINE;

ADULT; AGED; ANEMIA; APPLICATION SITE ERYTHEMA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTACT DERMATITIS; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY CANCER; ENZYME ACTIVITY; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; HYPERPIGMENTATION; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MYCOSIS FUNGOIDES; NAUSEA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; POSTINFLAMMATORY HYPERPIGMENTATION; PRIORITY JOURNAL; RACE DIFFERENCE; SIDE EFFECT; SKIN BIOPSY; TELANGIECTASIA; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOPSY; CARMUSTINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GUANINE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84861409206     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.2797     Document Type: Article

References (45)

1. Fung MA, Murphy MJ, Hoss DM, Grant-Kels JM. Practical evaluation and management of cutaneous lymphoma. 2002;46(3):325-357.
2. Ramsay DL, Meller JA, Zackheim HS. Topical treatment of early cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9(5):1031-1056.
3. Apisarnthanarax N, Talpur R, Duvic M. Treatment of cutaneous T cell lymphoma: current status and future directions. Am J Clin Dermatol. 2002;3(3):193-215. (Pubitemid 34533779)
4. Kim YH, Chow S, Varghese A, Hoppe RT. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol. 1999;135(1):26-32. (Pubitemid 29069513)
5. Kim YH, Jensen RA, Watanabe GL, Varghese A, Hoppe RT. Clinical stage IA (limited patch and plaque) mycosis fungoides: a long-term outcome analysis. Arch Dermatol. 1996;132(11):1309-1313. (Pubitemid 26386618)
6. Bunn PA Jr, Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Intern Med. 1994;121(8):592-602.
7. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31-39. (Pubitemid 46053039)
8. Zackheim HS, Epstein EH Jr, Crain WR. Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. J Am A cad Dermatol. 1990;22(5, pt 1):802-810. (Pubitemid 20154080)
9. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4(4):296-307. (Pubitemid 38525285)
10. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol. 2002;20(9):2388-2399. (Pubitemid 34441669)
11. Gerson SL, Willson JK. O6-alkylguanine-DNA alkyltransferase: a target for the modulation of drug resistance. Hematol Oncol Clin North Am. 1995;9(2):431-450.
12. Tong WP, Kirk MC, Ludlum DB. Formation of the cross-link 1-[N3-deoxycytidyl),2-[N1-deoxyguanosinyl]ethane in DNA treated with N,N′-bis(2-chloroethyl)-N-nitrosourea. Cancer Res. 1982;42(8):3102-3105. (Pubitemid 12041062)
13. Dolan ME, Young GS, Pegg AE. Effect of O6-alkylguanine pretreatment on the sensitivity of human colon tumor cells to the cytotoxic effects of chloroethylating agents. Cancer Res. 1986;46(9):4500-4504. (Pubitemid 16046878)
14. Trey JE, Gerson SL. The role of O6-alkylguanine DNA alkyltransferase in limiting nitrosourea-induced sister chromatid exchanges in proliferating human lymphocytes. Cancer Res. 1989;49(8):1899-1903. (Pubitemid 19106486)
15. Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res. 2006;12(2):328-331. (Pubitemid 43166117)
16. Aida T, Cheitlin RA, Bodell WJ. Inhibition of O6-alkylguanine-DNA- alkyltransferase activity potentiates cytotoxicity and induction of SCEs in human glioma cells resistant to 1,3-bis(2-chloroethyl)-1-nitrosourea. Carcinogenesis. 1987;8(9):1219-1223. (Pubitemid 17129981)
17. Gerson SL, Trey JE, Miller K. Potentiation of nitrosourea cytotoxicity in human leukemic cells by inactivation of O6-alkylguanine-DNA alkyltransferase. Cancer Res. 1988;48(6):1521-1527. (Pubitemid 18091200)
18. Dolan ME, Moschel RC, Pegg AE. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A. 1990;87(14):5368-5372.
19. Pegg AE, Boosalis M, Samson L, et al. Mechanism of inactivation of human O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine. Biochemistry. 1993; 32(45):11998-12006. (Pubitemid 23353637)
20. Dolan ME, Roy SK, Fasanmade AA, Paras PR, Schilsky RL, Ratain MJ. O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol. 1998;16(5):1803-1810.
21. Dolan ME, Mitchell RB, Mummert C, Moschel RC, Pegg AE. Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res. 1991;51(13):3367-3372.
22. Magull-Seltenreich A, Zeller WJ. Sensitization of human colon tumour cell lines to carmustine by depletion of O6-alkylguanine-DNA alkyltransferase. J Cancer Res Clin Oncol. 1995;121(4):225-229.
23. Gerson SL, Zborowska E, Norton K, Gordon NH, Willson JK. Synergistic efficacy of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to carmustine alone. Biochem Pharmacol. 1993;45(2):483-491. (Pubitemid 23042649)
24. Dolan ME, Pegg AE, Moschel RC, Grindey GB. Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-bis(2-chloroethyl)-1- nitrosourea (BCNU). Biochem Pharmacol. 1993;46(2):285-290. (Pubitemid 23218614)
25. Mitchell RB, Moschel RC, Dolan ME. Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation. Cancer Res. 1992;52(5):1171-1175.
26. Friedman HS, Kokkinakis DM, Pluda J, et al. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol. 1998;16 (11):3570-3575. (Pubitemid 28506770)
27. Spiro TP, Gerson SL, Liu L, et al. O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res. 1999;59(10):2402-2410. (Pubitemid 29242289)
28. Dolan ME, Posner M, Karrison T, et al. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res. 2002;8(8):2519-2523. (Pubitemid 34856334)
29. Schold SC Jr, Kokkinakis DM, Chang SM, et al. O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. Neuro Oncol. 2004;6(1):28-32. (Pubitemid 38139636)
30. Friedman HS, Pluda J, Quinn JA, et al. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2000;18(20):3522-3528.
31. Schilsky RL, Dolan ME, Bertucci D, et al. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res. 2000;6(8):3025-3031. (Pubitemid 30637724)
32. Weingart J, Grossman SA, Carson KA, et al. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol. 2007;25(4):399-404. (Pubitemid 350002988)
33. Quinn JA, Pluda J, Dolan ME, et al. Phase II trial of carmustine plus O(6)- benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol. 2002;20(9):2277-2283. (Pubitemid 34441654)
34. Batts ED, Maisel C, Kane D, et al. O6-benzylguanine and BCNU in multiple myeloma: a phase II trial. Cancer Chemother Pharmacol. 2007;60(3):415-421. (Pubitemid 46944590)
35. Gajewski TF, Sosman J, Gerson SL, et al. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clin Cancer Res. 2005;11(21):7861-7865. (Pubitemid 41611631)
36. Ryan CW, Dolan ME, Brockstein BB, et al. A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol. 2006;58(5):634-639. (Pubitemid 44167389)
37. Adams DM, Zhou T, Berg SL, Bernstein M, Neville K, Blaney SM; Children's Oncology Group. Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008;50(3):549-553. (Pubitemid 351155823)
38. Bunn PA Jr, Lamberg SI. Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep. 1979;63(4):725-728. (Pubitemid 9217604)
39. Smoller BR, Bishop K, Glusac E, Kim YH, Hendrickson M. Reassessment of histologic parameters in the diagnosis of mycosis fungoides. Am J Surg Pathol. 1995;19(12):1423-1430.
40. Stevens SR, Ke MS, Parry EJ, Mark J, Cooper KD. Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severityweighted assessment tool (SWAT). Arch Dermatol. 2002;138(1):42-48. (Pubitemid 34056233)
41. Lansigan F, Choi J, Foss FM. Cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 2008;22(5):979-996, x.
42. Zackheim HS, Epstein EH Jr, McNutt NS, Grekin DA, Crain WR. Topical carmustine (BCNU) for mycosis fungoides and related disorders: a 10-year experience. J Am Acad Dermatol. 1983;9(3):363-374. (Pubitemid 13051877)
43. Zackheim HS. Topical carmustine (BCNU) in the treatment of mycosis fungoides. Dermatol Ther. 2003;16(4):299-302. (Pubitemid 38044673)
44. Qin X, Zhou H, Liu L, Gerson SL. Transgenic expression of human MGMT blocks the hypersensitivity of PMS2-deficient mice to low dose MNU thymic lymphomagenesis. Carcinogenesis. 1999;20(9):1667-1673. (Pubitemid 29410543)
45. Dolan ME, McRae BL, Ferries-Rowe E, et al. O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents. Clin Cancer Res. 1999;5(8):2059-2064. (Pubitemid 29399258)